Anna Bowman

Anna Bowman

Auto-generated profile, based on publicly available information

Anna Bowman

University of Colorado

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2026 in Stroke
Verified
Journal Article
Closed access
RSRicha Sharma
Richa Sharma
KMKatelyn F. McNamara
Katelyn F. McNamara
EGElena Badillo Goicoechea
Elena Badillo Goicoechea
ABAnna Bowman
Anna Bowman
RCRussell Van Coevering
Russell Van Coevering
JSJames E. Siegler
James E. Siegler
BACKGROUND: Left ventricular (LV) dysfunction is a potential cardioembolic source of ischemic stroke, but its role in recurrent stroke risk and treatment response remains unclear. We explore whether LV injury associates with the risk of recurrent stroke and modifies the association between anticoagulation and stroke recurrence using real-world data. METHODS: We performed a multicenter, retrospective study of Cardiac Abnormalities in Stroke Prevention and Recurrence cohort across 27 US sites. Patients with LV ejection fraction ≥20% were included. LV injury, defined as LV ejection fraction 20% to 40% and wall motion abnormality, was the primary exposure and treatment effect modifier. The treatment of interest was anticoagulant versus antiplatelet therapy. The composite outcome included recurrent stroke, major bleeding, or death. Outcomes were evaluated using unadjusted and inverse probability weighting adjusted Cox proportional hazards models, with treatment effect modification tested by LV injury status. RESULTS: Among 2685 patients enrolled, 2328 with complete data were analyzed (median age, 65 years; 49.8% female; median follow-up, 1.6 years). LV injury was present in 310 patients (13.3%). Overall, 535 events occurred: 258 recurrent ischemic strokes, 28 hemorrhagic strokes, 67 major hemorrhages, and 256 deaths. LV injury was associated with a higher unadjusted risk of the primary outcome (hazard ratio [HR], 1.51 [95% CI, 1.21–1.87]), though nonsignificant after inverse probability weighting adjustment (adjusted HR, 1.29 [95% CI, 0.97–1.70]). In the LV injury subgroup, anticoagulation versus antiplatelet therapy was associated with a lower risk of the primary outcome (adjusted HR, 0.24 [95% CI, 0.10–0.59]), relative to the non-LV injury subgroup (adjusted HR, 1.28 [95% CI, 0.83–1.95]; p[LV-interaction], 0.001). Similar interactions were seen for EF 20% to 40% (versus >40%; adjusted HR, 0.19 [95% CI, 0.04–0.86]; p[LV-interaction], 0.001) and wall motion abnormality (versus no wall motion abnormality; adjusted HR, 0.33 [95% CI, 0.15–0.73]). CONCLUSIONS: After cryptogenic stroke, anticoagulation in those with LV injury was associated with lower rates of recurrent stroke, major bleeding, and death. These findings warrant confirmation in a dedicated randomized controlled trial. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06398366.

1 August 2026 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
HAHassan Aboul-Nour
Hassan Aboul-Nour
JSJames E. Siegler
James E. Siegler
STSean L. Thompson
Sean L. Thompson
PGPatrick A. Glover
Patrick A. Glover
JDJean-Philippe Auguste Daniel
Jean-Philippe Auguste Daniel
FNFadi Nahab
Fadi Nahab
Background and ObjectivesMultiple clinical trials have failed to show benefit of anticoagulation over antiplatelets in preventing recurrent stroke among patients with embolic stroke of undetermined...

15 September 2026 in Journal of the American Heart Association
Verified
Journal Article
Open access
FKFarhan Khan
Farhan Khan
CSChristoph Stretz
Christoph Stretz
SLSkylar Lewis
Skylar Lewis
DCDalia Chahien
Dalia Chahien
EGEric Goldstein
Eric Goldstein
SYShadi Yaghi
Shadi Yaghi
Background: Although the embolic stroke of undetermined source (ESUS) construct was proposed as a unifying concept for embolic‐appearing strokes without an identified cause, it includes patients with diverse and often unrecognized underlying mechanisms. This study investigates the differential rate of recurrent stroke according to the completeness of neurodiagnostic testing in a diverse multicenter cohort. Methods: This was a retrospective analysis of a multicenter observational cohort study (n=27 sites). ESUS was categorized into 3 groups: (1) established mechanism after further workup (ESUS‐E), (2) comprehensive diagnostic workup without an identified cause (ESUS 2.0), and (3) no advanced workup. The primary outcome of recurrent ischemic stroke was compared between ESUS with established mechanism and ESUS 2.0 versus ESUS with no advanced workup and was assessed using adjusted Cox proportional hazards models. Results: Among 2281 patients, the mean age was 65 years, and 50.1% were men. 694 (30.4%) classified as ESUS‐E, 1,243 (54.5%) classified as ESUS‐NAW, and 344 (15.1%) as ESUS 2.0. The ESUS 2.0 group had a significantly lower risk of recurrent stroke than both the group with ESUS with no advanced workup (adjusted hazard ratio [aHR], 0.31 [95% CI, 0.13–0.76]) and the group with ESUS with established mechanism (aHR, 0.35 [95% CI, 0.15–0.85]). Within the group with ESUS with established mechanism, cancer (aHR, 5.33 [95% CI, 2.09–13.63]) and nonstenosing atherosclerotic disease or arch atheroma (aHR, 3.40 [95% CI, 1.18–9.83]) were associated with significantly increased risk of recurrence when compared with the group with ESUS 2.0. Conclusions: These findings demonstrate a lower risk of recurrent stroke in patients classified as ESUS 2.0 than reported in prior ESUS trials and highlight the importance of age‐appropriate advanced diagnostic evaluation. Registration: URL: https://www.clinicaltrials.gov . Identifier: NCT06398366.